Novorapid Flextouch (Insulin Aspart)

Novorapid Flextouch, a rapid‑acting insulin analog, is used to manage blood glucose in diabetes and related hyperglycemic conditions.

• Diabetes mellitus type 1: provides rapid post‑meal insulin to match carbohydrate intake and reduce hyperglycemia.
• Diabetes mellitus type 2: added to oral agents or basal insulin for intensive glycemic control when meals cause spikes.
• Hospital‑related hyperglycemia: used for quick correction of elevated blood glucose in inpatient settings.

• Insulin aspart differs from human insulin by substitution of proline with aspartic acid at position B28, reducing hexamer formation and allowing rapid absorption after subcutaneous injection. The molecule binds to insulin receptors on muscle and adipose tissue, activating the receptor tyrosine kinase pathway, which promotes GLUT4 translocation and glucose uptake, while simultaneously inhibiting hepatic gluconeogenesis.

The most frequently reported reactions to rapid‑acting insulin analogues involve glucose regulation and injection site responses.

Common Side Effects

• Hypoglycemia: low blood glucose episodes, especially if meals are delayed or doses are excessive.
• Injection site pain or erythema: mild discomfort or redness at the injection site.
• Weight gain: modest increase associated with improved glycemic control.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects

• Severe hypoglycemia: profound low glucose requiring assistance.
• Anaphylactic reaction: rare systemic allergic response with rash, swelling, or respiratory difficulty.
• Hypokalemia: low potassium levels secondary to insulin‑driven cellular uptake.
• Insulin edema: fluid retention causing peripheral swelling.

When using Novorapid Flextouch, several precautions should be observed to ensure safety and effectiveness.

• Hypoglycemia risk: monitor blood glucose before meals and adjust dose as needed.
• Renal impairment: use cautiously and consider dose reduction in patients with reduced kidney function.
• Pregnancy considerations: only use if the potential benefit outweighs potential risk to the fetus.
• Alcohol consumption: may potentiate insulin‑induced hypoglycemia; advise patients to limit intake.
• Concomitant beta‑blockers: can mask hypoglycemia symptoms, requiring closer glucose monitoring.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin aspart may interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Major Interactions (Avoid)

• Beta‑blockers: can conceal hypoglycemia symptoms, making detection difficult.
• MAO inhibitors: may potentiate insulin’s hypoglycemic action.
• Concurrent use of other insulin products: increases risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or other oral hypoglycemics: additive glucose‑lowering effect raises hypoglycemia risk.
• Thiazide diuretics: may elevate blood glucose, requiring insulin dose adjustment.
• Corticosteroids: can increase insulin resistance, necessitating higher doses.
• Alcohol: can cause delayed hypoglycemia, especially with missed meals.